Eli Lilly's Latest Cancer Win Comes With a Big Caveat
This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) secured another regulatory boost for olomorasib after the FDA granted breakthrough therapy designation to the experimental drug as a standalone treatment for previously treated, advanced pancreatic cancer carrying the KRAS G12C mutation. The decision could …